In fact, in 2016, by combining morphology and genetic alterations, the WHO updated their guidelines, leading to the emergence of two entities based on the mutational status of the IDH gene: IDH wild-type and IDH mutated GBM [73]. This evidence concerns the gene IDH2 and glioblastoma.